NCT00344318View on ClinicalTrials.gov

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

806

Participants

Timeline

Start Date

August 7, 2006

Primary Completion Date

April 27, 2007

Study Completion Date

October 17, 2007

Conditions
Infections, Streptococcal
Interventions
BIOLOGICAL

Pneumococcal conjugate vaccine GSK1024850A

3 Intramuscular injections.

BIOLOGICAL

Prevenar

3 Intramuscular injections

BIOLOGICAL

Tritanrix-HepB

3 Intramuscular injections

BIOLOGICAL

Hiberix

Reconstituted with Tritanrix before injection

BIOLOGICAL

Polio Sabin.

3 oral doses.

BIOLOGICAL

Poliorix.

3 intramuscular injections

Trial Locations (7)

1781

GSK Investigational Site, City of Muntinlupa

50345

GSK Investigational Site, Wroclaw

80-394

GSK Investigational Site, Gdansk

91-347

GSK Investigational Site, Lodz

55-100

GSK Investigational Site, Trzebnica

89-500

GSK Investigational Site, Tuchola

52-312

GSK Investigational Site, Wroclaw

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00344318 - Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine | Biotech Hunter | Biotech Hunter